TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351)

Article activity feed

1. Version published to 10.1128/spectrum.00472-21

   Sep 3, 2021
2. 

   ScreenIT

   Apr 9, 2021

   SciScore for 10.1101/2021.04.06.438540: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Anti‐SARS‐CoV‐2 N protein antibody was purchased from Sino Biological Inc (Beijing, China)	Anti‐SARS‐CoV‐2 N protein antibody suggested: None Anti‐SARS‐CoV‐2 N protein suggested: None
   Alexa Fluor 488 goat anti‐rabbit IgG (H + L) secondary antibody and Hoechst 33342 were purchased from Molecular Probes.	Alexa Fluor 488 goat anti‐rabbit IgG suggested: None anti‐rabbit IgG suggested: None
   Anti-SARS-CoV-2 nucleocapsid (N) primary antibody, 488-conjugated goat …

   SciScore for 10.1101/2021.04.06.438540: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Anti‐SARS‐CoV‐2 N protein antibody was purchased from Sino Biological Inc (Beijing, China)	Anti‐SARS‐CoV‐2 N protein antibody suggested: None Anti‐SARS‐CoV‐2 N protein suggested: None
   Alexa Fluor 488 goat anti‐rabbit IgG (H + L) secondary antibody and Hoechst 33342 were purchased from Molecular Probes.	Alexa Fluor 488 goat anti‐rabbit IgG suggested: None anti‐rabbit IgG suggested: None
   Anti-SARS-CoV-2 nucleocapsid (N) primary antibody, 488-conjugated goat anti-rabbit IgG secondary antibody and Hoechst 33342 were treated to the cells for immunofluorescence.	Anti-SARS-CoV-2 nucleocapsid (N) suggested: None anti-rabbit IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Virus and cells: Vero and Vero E6 cells were obtained from the American Type Culture Collection (ATCC CCL-81 and C1008, respectively) and maintained at 37°C with 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM; Welgene), supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 2% antibiotic-antimycotic solution (Gibco).	Vero E6 suggested: None
   Calu-3 cells were seeded at 2.0 × 104cells per well with Eagle’s Minimum Essential Medium (EMEM, ATCC) supplemented with 20% heat-inactivated fetal bovine serum (FBS), 1%	Calu-3 suggested: None
   For viral infection, plates were transferred into the BSL‐3 containment facility and SARS‐CoV‐2 was added at a multiplicity of infection of 0.008 for Vero cells and 0.2 for Calu-3 cells.	Vero suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
   Software and Algorithms
   Sentences	Resources
   DRCs were generated using Prism7 software (GraphPad).	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.04.06.438540v1 on bioRxiv

   Apr 8, 2021